Yolanda Gomez-Galvez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1787172/publications.pdf

Version: 2024-02-01

6 284 4 5 papers citations h-index g-index

6 6 6 543
all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Potential of the cannabinoid CB2 receptor as a pharmacological target against inflammation in Parkinson's disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 64, 200-208.	4.8	154
2	Cannabinoid–dopamine interactions in the physiology and physiopathology of the basal ganglia. British Journal of Pharmacology, 2016, 173, 2069-2079.	5 . 4	56
3	Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson's disease: possible involvement of different binding sites at the PPARγ receptor. Journal of Neuroinflammation, 2018, 15, 19.	7.2	47
4	Targeting the cannabinoid CB 2 receptor to attenuate the progression of motor deficits in LRRK2-transgenic mice. Pharmacological Research, 2016, 110, 181-192.	7.1	25
5	Quantitative proteomic profiling of the rat substantia nigra places glial fibrillary acidic protein at the hub of proteins dysregulated during aging: Implications for idiopathic Parkinson's disease. Journal of Neuroscience Research, 2020, 98, 1417-1432.	2.9	2
6	Paclitaxel is effective for controlling astrocyte proliferation in vitro: Implications for generating ventral mesencephalic cultures enriched with dopamine neurons. Journal of Neuroscience Methods, 2021, 351, 109065.	2.5	0